Review of methods for estimating the prevalence of rare diseases

Abstract

One of the main challenges in rare diseases is the unavailability of reliable estimates of prevalence and incidence. The lack of epidemiological data makes planning for therapeutic and management options challenging. Methods for estimating the prevalence and incidence of rare and genetic diseases primarily rely on the availability of accurate national patient registries or databases of birth defects. This gap is wider in Low- and Middle-Income countries (LMICs) such as India, where currently, the estimates of prevalence and incidence are either unknown or data from developed countries have to be used as a proxy. Here, we analyzed the current methods used to estimate the prevalence and incidence of rare genetic diseases to provide recommendations in the form of a decision tree to select the most feasible method, particularly in resource-constrained environments such as India. We selected ten rare diseases of shared importance to the Indo US Organization for Rare Diseases (IndoUSrare) and its Patients Alliance members for analysis. Our analysis suggests that retrospective study designs are the most commonly used method to estimate the prevalence and incidence of rare diseases. We propose a generalized decision tree or flowchart to aid epidemiology researchers during the selection of methods for estimating the prevalence and incidence of a rare or genetic disease.

Keywords

Rare disease / prevalence / incidence / epidemiology / genetic disease

References

[1] What is a rare disease? Available from:https://www.eurordis.org/content/what-rare-disease[Last accessed on 1 Feb 2024]

[2] Rode - 2005 - Rare diseases: understanding this public health priority. Available from:https://www.eurordis.org/publications/rare-diseases-understanding-this-public-health-priority[Last accessed on 1 Feb 2024]

[3] The power of being counted. Available from:https://rare-x.org/case-studies/the-power-of-being-counted[Last accessed on 1 Feb 2024]

[4] Nguengang Wakap S,Olry A.Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database.Eur J Hum Genet2020;28:165-73.

[5] Genetic and rare diseases information center (GARD) - an NCATS program providing information about rare or genetic diseases. Available from: https://rarediseases.info.nih.gov/[Last accessed on 1 Feb 2024]

[6] Tisdale A,Nathan R.The IDeaS initiative: pilot study to assess the impact of rare diseases on patients and healthcare systems.Orphanet J Rare Dis2021;16:429.

[7] Crisafulli S,Fontana A,Messina S.Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis.Orphanet J Rare Dis2020;15:141.

[8] Angelis A,Kanavos P.Socio-economic burden of rare diseases: A systematic review of cost of illness evidence.Health Policy2015;119:964-79.

[9] Andreu P,Child C,Cioffi G. The burden of rare diseases: an economic evaluation. Available from:https://chiesirarediseases.com/assets/pdf/chiesiglobalrarediseases.whitepaper-feb.-2022_production-proof.pdf[Last accessed on 1 Feb 2024]

[10] Yang G,Pariser A,Sullivan J.The national economic burden of rare disease in the United States in 2019.Orphanet J Rare Dis2022;17:163

[11] National policy for rare diseases. Available from:https://main.mohfw.gov.in/sites/default/files/Final%20NPRD%2C%202021.pdf[Last accessed on 1 Feb 2024]

[12] Richter T,Babela R.International Society for Pharmacoeconomics and Outcomes Research Rare Disease Special Interest GroupRare disease terminology and definitions-a systematic global review: report of the ISPOR Rare disease special interest group.Value Health2015;18:906-14

[13] Orphan Drug Act of 1983. Available from:https://www.govinfo.gov/content/pkg/STATUTE-96/pdf/STATUTE-96-Pg2049.pdf[Last accessed on 1 Feb 2024]

[14] Rare diseases. Available from:https://research-and-innovation.ec.europa.eu/research-area/health/rare-diseases_en[Last accessed on 1 Feb 2024]

[15] National cancer institute. Definition of prevalence. Available from:https://www.cancer.gov/publications/dictionaries/cancer-terms/def/prevalence[Last accessed on 1 Feb 2024]

[16] Rajasimha HK,Ramamoorthy P.Organization for rare diseases India (ORDI) - addressing the challenges and opportunities for the Indian rare diseases' community.Genet Res2014;96:e009

[17] Frequently asked questions (FAQs) on new drugs and clinical trials. Available from:https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadPublic_NoticesFiles/faqnd.pdf[Last accessed on 1 Feb 2024]

[18] Dharssi S,Harold M.Review of 11 national policies for rare diseases in the context of key patient needs.Orphanet J Rare Dis2017;12:63

[19] Hayashi S.35 years of Japanese policy on rare diseases.Lancet2008;372:889-90

[20] Rawson NS.Health technology assessment of new drugs for rare disorders in Canada: impact of disease prevalence and cost.Orphanet J Rare Dis2017;12:59

[21] Song P,Inagaki Y,Tang W.Rare diseases, orphan drugs, and their regulation in Asia: Current status and future perspectives.Intractable Rare Dis Res2012;1:3-9. PMCID:PMC4204590

[22] Hsiang NC,Gau CS,Chang LC.The impact of the rare disease and Orphan Drug Act in Taiwan.J Food Drug Anal2021;29:717-25.

[23] U.S. and World Population Clock. Available from:https://www.census.gov/popclock/[Last accessed on 1 Feb 2024]

[24] Wagstaff A.A comprehensive assessment of universal health coverage in 111 countries: a retrospective observational study.Lancet Glob Health2020;8:e39-49

[25] Hooley B,Fink G.Health insurance coverage in low-income and middle-income countries: progress made to date and related changes in private and public health expenditure.BMJ Glob Health2022;7:e008722 PMCID:PMC9092126

[26] Seyi-Olajide JO,Guadagno E,Poenaru D.Screening methods for congenital anomalies in low and lower-middle income countries: A systematic review.J Pediatr Surg2023;58:986-93

[27] Verhaart IEC,Wilson IJ.Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review.Orphanet J Rare Dis2017;12:124. PMCID:PMC5496354

[28] SCN8A Interactive Website. Available from:https://www.scn8a.net/[Last accessed on 1 Feb 2024]

[29] About SCN8A. Available from:https://www.thecutesyndrome.com/about-scn8a.html[Last accessed on 1 Feb 2024]

[30] CSNK2A1 Foundation. Published research. Available from:https://www.csnk2a1foundation.org/published-research/[Last accessed on 1 Feb 2024]

[31] Groft SC. Rare Diseases - Avoiding Misperceptions and Establishing Realities: The Need for Reliable Epidemiological Data. In: Posada de la Paz M, Groft SC, editors. Rare Diseases Epidemiology. Dordrecht: Springer Netherlands; 2010. pp. 3-14.

[32] Walter AL,Rassouli F,Brutsche MH.Diagnostic precision and identification of rare diseases is dependent on distance of residence relative to tertiary medical facilities.Orphanet J Rare Dis2021;16:131. PMCID:PMC7983389

[33] Rajasimha H. Tackling Rare Disease in India. Available from:https://www.insideprecisionmedicine.com/news-and-features/tackling-rare-disease-in-india/ [Last accessed on 1 Feb 2024]

[34] Bhattacharya S,Majumder PP. Rare diseases in India: current knowledge and new possibilities. Available from:http://insa.nic.in/writereaddata/UpLoadedFiles/PINSA/2016_Art93.pdf[Last accessed on 1 Feb 2024]

[35] Christianson A,Modell B. Global report on birth defects. The hidden toll of dying and disabled children. Available from:https://onprem.marchofdimes.org/materials/global-report-on-birth-defects-the-hidden-toll-of--d2unzZI5_VWOaLZnw6iHcx7hbpMWtWzTuIOU3DabcVY.pdf[Last accessed on 1 Feb 2024]

[36] Mohanty D,Gorakshakar AC.Prevalence of β-thalassemia and other haemoglobinopathies in six cities in India: a multicentre study.J Community Genet2013; 4:33-42. PMCID:PMC3537975

[37] Nadkarni AH,Sawant PM.The phenotypic and molecular diversity of hemoglobinopathies in India: A review of 15 years at a referral center.Int J Lab Hematol2019;41:218-26

[38] Kabra M.Dietary management of inborn errors of metabolism.Indian J Pediatr2022;69:421-6.

[39] Sachdeva A.Dietary interventions for rare metabolic disorders - now available in India!.Indian Pediatr2017;54:909-10.

[40] Verma IC,Dua Puri R.Down syndrome in India--diagnosis, screening, and prenatal diagnosis.Clin Lab Med2012;32:231-48.

[41] Kar A,Dharmarajan S.Epidemiology & social costs of haemophilia in India.Indian J Med Res2014;140:19-31. PMCID:PMC4181156

[42] IndoUSrare. Rare Disease Organization - IndoUSrare's Global Collaboration. Available from:https://www.indousrare.org/[Last accessed on 1 Feb 2024]

[43] Veeramah KR,Meisler MH.De novo pathogenic SCN8A mutation identified by whole-genome sequencing of a family quartet affected by infantile epileptic encephalopathy and SUDEP.Am J Hum Genet2012;90:502-10. PMCID:PMC3309181

[44] Okur V,Henderson L.De novo mutations in CSNK2A1 are associated with neurodevelopmental abnormalities and dysmorphic features.Hum Genet2016;135:699-705.

[45] ICD-10 version:2019. Available from:https://icd.who.int/browse10/2019/en[Last accessed on 1 Feb 2024]

[46] ICD-11 for mortality and morbidity statistics. Available from:https://icd.who.int/browse11/l-m/en[Last accessed on 1 Feb 2024]

[47] Horn MA,Abdelnoor M,Tallaksen CM.Adrenoleukodystrophy in Norway: high rate of de novo mutations and age-dependent penetrance.Pediatr Neurol2013;48:212-9.

[48] Heim P,Hoffmann B.Leukodystrophy incidence in Germany.Am J Med Genet1997;71:475-8.

[49] Wiens K,Choi H.A report on state-wide implementation of newborn screening for X-linked Adrenoleukodystrophy.Am J Med Genet A2019;179:1205-13. PMCID:PMC6619352

[50] Nalysnyk L,Simeone JC,Weinreb N.Gaucher disease epidemiology and natural history: a comprehensive review of the literature.Hematology2017;22:65-73.

[51] Puckett Y,Montaño AM.Epidemiology of mucopolysaccharidoses (MPS) in United States: challenges and opportunities.Orphanet J Rare Dis2021;16:241. PMCID:PMC8164808

[52] Malm G,Månsson JE.Mucopolysaccharidoses in the Scandinavian countries: incidence and prevalence.Acta Paediatr2008;97:1577-81.

[53] Kulas Søborg ML,Quitzau Mortensen L,Burcharth J.Establishment and baseline characteristics of a nationwide Danish cohort of patients with Ehlers-Danlos syndrome.Rheumatology2017;56:763-7.

[54] Symonds JD,Stewart K.Incidence and phenotypes of childhood-onset genetic epilepsies: a prospective population-based national cohort.Brain2019;142:2303-18. PMCID:PMC6658850

[55] Ware TL,Grinton BE.Epidemiology and etiology of infantile developmental and epileptic encephalopathies in Tasmania.Epilepsia Open2019;4:504-10. PMCID:PMC6698683

[56] Kridin K.Epidemiology of Pemphigus.JID Innov2021;1:100004. PMCID:PMC8659392

[57] Higgins TS,Sinacori JT.Laryngeal mucous membrane pemphigoid: a systematic review and pooled-data analysis.Laryngoscope2010;120:529-36.

[58] Persson MSM,Grainge MJ,Grindlay D.The global incidence of bullous pemphigoid: a systematic review and meta-analysis.Br J Dermatol2022;186:414-25.

[59] Mah JK,Dykeman J,Pringsheim T.A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy.Neuromuscul Disord2014;24:482-91.

[60] Wang J,Bao X.SCN8A mutations in Chinese patients with early onset epileptic encephalopathy and benign infantile seizures.BMC Med Genet2017;18:104. PMCID:PMC5604297

[61] Kong W,Gao Y.SCN8A mutations in Chinese children with early onset epilepsy and intellectual disability.Epilepsia2015;56:431-8.

[62] Poorthuis BJ,Kleijer WJ.The frequency of lysosomal storage diseases in The Netherlands.Hum Genet1999;105:151-6.

[63] Poupetová H,Berná L,Kozich V.The birth prevalence of lysosomal storage disorders in the Czech Republic: comparison with data in different populations.J Inherit Metab Dis2010;33:387-96. PMCID:PMC2903693

[64] Murila F,Ireri JM.Gaucher's disease at a national referral hospital.East Afr Med J2008;85:455-8.

[65] Meikle PJ,Clague AE.Prevalence of lysosomal storage disorders.JAMA1999;281:249-54.

[66] Sereni C,Aubourg P,Feingold J.Adrenoleukodystrophy in France: an epidemiological study.Neuroepidemiology1993;12:229-33.

[67] Kridin K.Pemphigus group: overview, epidemiology, mortality, and comorbidities.Immunol Res2018;66:255-70.

[68] Hanany M,Sharon D.Worldwide carrier frequency and genetic prevalence of autosomal recessive inherited retinal diseases.Proc Natl Acad Sci U S A2020;117:2710-6

[69] Shourick J,Jannot AS.Assessing rare diseases prevalence using literature quantification.Orphanet J Rare Dis2021;16:139 PMCID:PMC7980535

[70] Şenel E,Alkan RM.Bibliometric analysis on global Behçet disease publications during 1980-2014: is there a Silk Road in the literature?.J Eur Acad Dermatol Venereol2017;31:518-22.

[71] Mishra RK,Esam H.Diffuse panbronchiolitis research in MEDLINE (1969-2017): report of a bibliometric analysis.Respir Investig2018;56:312-9.

[72] Frigotto ML.A few special cases: scientific creativity and network dynamics in the field of rare diseases.Scientometrics2011;89:397-420.

[73] Sweileh WM.Bibliometric analysis of literature on toxic epidermal necrolysis and Stevens-Johnson syndrome: 1940 - 2015.Orphanet J Rare Dis2017;12:14. PMCID:PMC5242056

[74] Czech M,Atikeler K.A review of rare disease policies and orphan drug reimbursement systems in 12 eurasian countries.Front Public Health2019;7:416 PMCID:PMC6997877

[75] Initiatives by the Government for treatment of rare diseases. Available from:https://pib.gov.in/PressReleasePage.aspx?PRID=1846230[Last accessed on 1 Feb 2024]

[76] Chaube P,Choudhury MC.Expansion of India's national child healthcare programme, Rashtriya Bal Swasthya Karyakram (RBSK), for rare disease management : a health policy perspective.Orphanet J Rare Dis2023;18:145 PMCID:PMC10262469

[77] Smedley D,Martin A.100,000 Genomes Project Pilot Investigators100,000 genomes pilot on rare-disease diagnosis in health care - preliminary report.N Engl J Med2021;385:1868-80.

[78] Sivasubbu S.GUaRDIAN ConsortiumGenomics of rare genetic diseases-experiences from India.Hum Genomics2019;14:52. PMCID:PMC6760067

[79] Nakatsuka N,Rai N.The promise of discovering population-specific disease-associated genes in South Asia.Nat Genet2017;49:1403-7. PMCID:PMC5675555

[80] Singh I,Mukherjee O.North and South Indian populations share a common ancestral origin of Friedreich's ataxia but vary in age of GAA repeat expansion.Ann Hum Genet2010;74:202-10.

[81] Venugopal A,Eruppakotte N,Breezevilla SC.Monogenic diseases in India.Mutat Res Rev Mutat Res2018;776:23-31.

[82] Kaur A.Chromosomal abnormalities: genetic disease burden in India.Int J Hum Genet2010;10:1-14.

[83] Serjeant GR.The natural history of sickle cell disease.Cold Spring Harb Perspect Med2013;3:a011783 PMCID:PMC3784812

[84] Rechtman L,Wagner L,Kaye W.Racial and ethnic differences among amyotrophic lateral sclerosis cases in the United States.Amyotroph Lateral Scler Frontotemporal Degener2015;16:65-71 PMCID:PMC4389704

[85] Shum BOV,Navilebasappa A.Racially equitable diagnosis of cystic fibrosis using next-generation DNA sequencing: a case report.BMC Pediatr2021;21:154 PMCID:PMC8011156

[86] Lachmann RH,Halsall D.Twin pairs showing discordance of phenotype in adult Gaucher's disease.QJM2004;97:199-204.

[87] Di Rocco M,Caruso U.Monozygotic twins with X-linked adrenoleukodystrophy and different phenotypes.Ann Neurol2001;50:424.

[88] Meisler MH.SCN8A encephalopathy: mechanisms and models.Epilepsia2019;60:S86-91. PMCID:PMC6953611

[89] Orphanet report series - prevalence of rare diseases: Bibliographic data. Available from:https://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_alphabetical_list.pdf[Last accessed on 1 Feb 2024]

[90] Rushforth A,Mongeon P. How does undone science get funded? A bibliometric analysis linking rare diseases publications to national and European funding sources. Available from:https://arxiv.org/abs/1802.05945[Last accessed on 1 Feb 2024]

[91] Bishop DV.Which neurodevelopmental disorders get researched and why?.PLoS One2010;5:e15112.

[92] Dickersin K,Chalmers TC,Smith H Jr.Publication bias and clinical trials.Control Clin Trials1987;8:343-53.

[93] Schulman JL. What's New for 2011 MeSH®. Available from:https://www.nlm.nih.gov/pubs/techbull/nd10/nd10_mesh.html[Last accessed on 1 Feb 2024]

[94] OpenAI. ChatGPT. Available from:https://chat.openai.com/chat[Last accessed on 1 Feb 2024]

[95] FDA issues draft guidances on real-world evidence, prepares to publish more in future. Available from:https://www.fda.gov/drugs/news-events-human-drugs/fda-issues-draft-guidances-real-world-evidence-prepares-publish-more-future[Last accessed on 1 Feb 2024]

[96] Khera HK,Karur RT,Kartha RV.Building cross-border collaborations to increase diversity and accelerate rare disease drug development - meeting report from the inaugural IndoUSrare Annual Conference 2021.Ther Adv Rare Dis2022;3:26330040221133124. PMCID:PMC10032468